Join our mailing list and receive the monthly BioVox newsletter for free!

RELATED ARTICLES
Inception of anaRIC biologics as Anacura and RIC combine R&D and GMP activities

With the purpose of supporting customers throughout their entire biological drug development process, GMP specialist Anacura and the R&D-focused R…


Liquid Biopsy is Cost-Effective for Biopsy Selection in prostate cancer

MDxHealth today announced BJU International published a study demonstrating that its SelectMDx for Prostate Cancer test can reduce overdiagnosis a…


MDx Health's SelectMDx to be Distributed Across Middle East by IPS Genomix

MDx Health gains market access of the Middle East via partner IPS Genomix.

POPULAR TAGS

MITHRA RECEIVES GMP APPROVAL FOR MYRING™ PRODUCTION

Written by LVS on in the category news with the tags .


Mithra, the women’s health sepcialist, has announced that the Mithra CDMO1 has received Good Manufacturing Practice (GMP) approval for the production line of Myring, a combined hormonal contraceptive vaginal ring made of ethylene vinyl acetate copolymers (EVA).

Following the GMP approval by AFMPS, the Belgian Federal Agency for Medicines and Health Products, Mithra will be able to ship its first commercial batches in the European Union once marketing approval has been received. The Company is on track to file for marketing approval in both Europe and the United States in Q2 2017.

Myring’s originator product, Nuvaring, will go off patent in April 2018, allowing other products, such as Myring, to enter the US and European market. The vaginal ring market in Europe and the US is valued at EUR 143m and EUR 740m2 respectively.

Mithra recently announced a 10-year license and supply agreement with Gynial GmbH, for the commercialization of Myring in Austria. This followed news in February of an exclusive long-term license and supply agreement with Mayne Pharma, a leading specialty pharmaceutical company, for the commercialization of Myring in the US.

François Fornieri, CEO of Mithra, commented: "GMP approval of our manufacturing line is an important milestone for our vaginal contraceptive Myring as well as for Mithra’s manufacturing and development capabilities at our dedicated CDMO. We already have an excellent partnership in the US with Mayne Pharma and recently announced a further licensing agreement for MyringTM in Austria. Today’s GMP accreditation will further assist ongoing discussions with potential licensing and distribution partners in Europe and other key markets.”

Read more about: .

RELATED ARTICLES
Inception of anaRIC biologics as Anacura and RIC combine R&D and GMP activities

With the purpose of supporting customers throughout their entire biological drug development process, GMP specialist Anacura and the R&D-focused R…


Liquid Biopsy is Cost-Effective for Biopsy Selection in prostate cancer

MDxHealth today announced BJU International published a study demonstrating that its SelectMDx for Prostate Cancer test can reduce overdiagnosis a…


MDx Health's SelectMDx to be Distributed Across Middle East by IPS Genomix

MDx Health gains market access of the Middle East via partner IPS Genomix.

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

UGent KU Leuven Biowin Janssen XpandInnovation Itera Life Science Turnstone Flanders.bio GSK V-Bio Ventures

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.